

In-Common Laboratories Head Office: 57 Gervais Drive North York, Ontario M3C 1Z2 (416) 422-3000 Toll Free: (888) 285-7817 www.ICLabs.ca	Patient Name TEST, SAMPLE	Sex U	Date of Birth (mm/dd/yyyy) MM/DD/YYYY
Client Name Client Address 1 Client Address 2 City, Province, Postal Code, Country	Order ID 1234567890	Health Number XXXXXXXXXXJP	Client File No: Report Copied To: Report Printed 12/07/2023 3:00PM
	ICL Login Date (mm/dd/yyyy) MM/DD/YYYY HH:MM AM	Authorized Requester Doctor, ICL, MD	

Streptococcus pneumoniae Antibodies - IgG 23 Serotypes MAID, Serum

Sample ID: QST23100500026

Final - Approved 10/17/2023 11:08PM

Collection Date/Time (mm/dd/yyyy)
09/22/2023 1:56PM

Order Choice PRE-VACCINATION TESTING
 Comments: 10/5/2023 10:05
 Testing performed at: EZ, Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano, CA, 92675-2042, Laboratory Director: Irina Maramica MD, PhD, MBA

TEST	RESULT	FLAG	NORMAL/THERAPEUTIC RANGE	UNITS	TEST SITE
SEROTYPE 1 (1)	<0.3				EZ
SEROTYPE 2 (2)	<0.3				EZ
SEROTYPE 3 (3)	<0.3				EZ
SEROTYPE 4 (4)	<0.3				EZ
SEROTYPE 5 (5)	<0.3				EZ
SEROTYPE 8 (8)	<0.3				EZ
SEROTYPE 9 (9N)	<0.3				EZ
SEROTYPE 12 (12F)	<0.3				EZ
SEROTYPE 14 (14)	<0.3				EZ
SEROTYPE 17 (17F)	<0.3				EZ
SEROTYPE 19 (19F)	85.9				EZ
SEROTYPE 20 (20)	<0.3				EZ
SEROTYPE 22 (22F)	<0.3				EZ
SEROTYPE 23 (23F)	<0.3				EZ
SEROTYPE 26 (6B)	<0.3				EZ
SEROTYPE 34 (10A)	<0.3				EZ
SEROTYPE 43 (11A)	<0.3				EZ
SEROTYPE 51 (7F)	<0.3				EZ
SEROTYPE 54 (15B)	<0.3				EZ
SEROTYPE 56 (18C)	<0.3				EZ
SEROTYPE 57 (19A)	29.4				EZ
SEROTYPE 68 (9V)	<0.3				EZ
SEROTYPE 70 (33F)	<0.3				EZ

Serologic correlates of protection against pneumococcal disease have not been rigorously established for all

In-Common Laboratories
 Head Office: 57 Gervais Drive
 North York, Ontario M3C 1Z2
 (416) 422-3000
 Toll Free: (888) 285-7817
 www.ICLabs.ca

Patient Name
TEST, SAMPLE

Sex
U

Date of Birth (mm/dd/yyyy)
MM/DD/YYYY

Order ID
1234567890

Client File No:

Report Copied To:

Client Name
 Client Address 1
 Client Address 2 City, Province,
 Postal Code,
 Country

Health Number
XXXXXXXXXXJP

Report Printed
12/07/2023 3:00PM

ICL Login Date (mm/dd/yyyy)
MM/DD/YYYY HH:MM AM

Authorized Requester
Doctor, ICL, MD

Streptococcus pneumoniae Antibodies - IgG 23
Serotypes MAID, Serum

Sample ID: QST23100500026

Final - Approved 10/17/2023 11:08PM

Collection Date/Time (mm/dd/yyyy)
 09/22/2023 1:56PM

Order Choice PRE-VACCINATION TESTING
 Comments: 10/5/2023 10:05

Testing performed at: EZ, Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano, CA, 92675-2042, Laboratory Director: Irina Maramica MD, PhD, MBA

TEST	RESULT	FLAG	NORMAL/THERAPEUTIC RANGE	UNITS	TEST SITE
------	--------	------	--------------------------	-------	-----------

patient populations. Published data and expert consensus (including WHO) suggest protection from invasive disease usually occurs at levels $\geq 0.3-0.50$ mcg/mL for healthy children receiving pneumococcal conjugate vaccines. Higher titers may be necessary to protect from non-invasive infection (e.g., pneumonia, otitis, sinusitis). Expert opinion suggests that a cut-off of ≥ 1.3 mcg/mL may be a more relevant value to assess antibody responses after pneumococcal polysaccharide vaccines or for immunocompromised patients. In addition to antibody quantity, protection also depends on antibody avidity and opsonophagocytic activity. Some experts consider that post-vaccination (4-6 weeks) IgG seroconversion and/or 2- to 4-fold rise in IgG titers for $>50\%$ to 70% of vaccine serotypes demonstrates a normal post-vaccine serologic response. Persons with high initial serotype-specific titers may have less robust responses.

Quest Diagnostics uses a multi-analyte immunodetection (MAID) method. The method employs the Luminex flow cytometric system which measures multiple analytes simultaneously. The FDA standard reference serum 89-S is used as the calibration standard. Results are reported in mcg/mL.

This assay detects all of the 23 of the serotypes in the 23-valent polysaccharide vaccine and 12 of the 13 serotypes in the 13-valent conjugate vaccine.

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and used for clinical purposes.

For additional information, please refer to <http://education.questdiagnostics.com/faq/FAQ181>
 (This link is being provided for informational/

In-Common Laboratories Head Office: 57 Gervais Drive North York, Ontario M3C 1Z2 (416) 422-3000 Toll Free: (888) 285-7817 www.ICLabs.ca	Patient Name TEST, SAMPLE	Sex U	Date of Birth (mm/dd/yyyy) MM/DD/YYYY
Client Name Client Address 1 Client Address 2 City, Province, Postal Code, Country	Order ID 1234567890	Health Number XXXXXXXXXXJP	Client File No: Report Copied To: Report Printed 12/07/2023 3:00PM
	ICL Login Date (mm/dd/yyyy) MM/DD/YYYY HH:MM AM	Authorized Requester Doctor, ICL, MD	

Streptococcus pneumoniae Antibodies - IgG 23 Serotypes MAID, Serum Sample ID: QST23100500026

Final - Approved 10/17/2023 11:08PM Collection Date/Time (mm/dd/yyyy)
09/22/2023 1:56PM

Order Choice PRE-VACCINATION TESTING
 Comments: 10/5/2023 10:05
 Testing performed at: EZ, Quest Diagnostics/Nichols SJC-San Juan Capistrano,, 33608 Ortega Hwy, San Juan Capistrano, CA, 92675-2042, Laboratory Director: Irina Maramica MD, PhD, MBA

TEST	RESULT	FLAG	NORMAL/THERAPEUTIC RANGE	UNITS	TEST SITE
	educational purposes only.)				

Reporting Laboratories:
 (1) QST-Quest, Quest Diagnostics,